Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems DOI Creative Commons
Matteo Perra, Ines Castangia, Matteo Aroffu

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 21, 2025

Cancer remains the second leading cause of death globally, driving need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% recently approved anticancer drugs. Despite their potential, early clinical trials faced challenges due severe side effects, prompting advancements in delivery systems such as antibody-maytansinoid conjugates (AMCs). This review highlights activity maytansinoids, with a focus on AMCs designed target cancer cells specifically. Preclinical and studies show that AMCs, including FDA-approved drugs like Kadcyla Elahere, effectively inhibit tumor growth while reducing systemic toxicity. Key developments include improved synthesis methods, linker chemistry payload design. Ongoing research aims enhance safety efficacy integrate nanotechnology drug delivery, identify novel therapeutic targets. These hold potential transform maytansinoid-based treatments future.

Language: Английский

Maytansinoids in cancer therapy: advancements in antibody–drug conjugates and nanotechnology-enhanced drug delivery systems DOI Creative Commons
Matteo Perra, Ines Castangia, Matteo Aroffu

et al.

Discover Oncology, Journal Year: 2025, Volume and Issue: 16(1)

Published: Jan. 21, 2025

Cancer remains the second leading cause of death globally, driving need for innovative therapies. Among natural compounds, maytansinoids have shown significant promise, contributing to nearly 25% recently approved anticancer drugs. Despite their potential, early clinical trials faced challenges due severe side effects, prompting advancements in delivery systems such as antibody-maytansinoid conjugates (AMCs). This review highlights activity maytansinoids, with a focus on AMCs designed target cancer cells specifically. Preclinical and studies show that AMCs, including FDA-approved drugs like Kadcyla Elahere, effectively inhibit tumor growth while reducing systemic toxicity. Key developments include improved synthesis methods, linker chemistry payload design. Ongoing research aims enhance safety efficacy integrate nanotechnology drug delivery, identify novel therapeutic targets. These hold potential transform maytansinoid-based treatments future.

Language: Английский

Citations

1